Therapeutic Advances in Psychopharmacology delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of psychopharmacology.

The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in psychopharmacology, providing a forum in print and online for publishing the highest quality articles in this area. The editors welcome articles of current interest on research across all areas of psychopharmacology, including anticonvulsants (for psychiatric disease), antidepressants, antimanic agents, antipsychotics, anxiolytics, drugs for ADHD, drugs for alcohol/opiate withdrawal, drugs for behavioural disturbance, drugs for dementia, drugs for substance misuse, drugs of misuse, hypnotics, mood stabilizers and psychostimulants.

It publishes expert opinion reviews (including single-drug and drug class reviews), narrative reviews and analysis of published guidelines (as editorials or reviews). Original research manuscripts of well-designed trials are also welcomed that show drug or drug class efficacy in a particular disease or therapeutic area. The journal strongly encourages the submission of original research with positive or negative results.

The journal adheres to a blind review process in which the reviewer's name is routinely withheld from the author unless the reviewer requests a preference for their identity to be revealed. Manuscripts are reviewed by at least two referees - a first editorial decision is generally reached within 3 weeks of submission. Online publication of articles occurs within 7 weeks from acceptance. Further information for contributors is provided on the back pages of each issue and online.

For all commercial sales and sponsorship enquiries, including advertising, reprints and supplements, please contact:

Commercial Sales Team, London, UK
Tel. +44 20 7336 1205
Email. reprints@sagepub.co.uk

This journal is a member of the Committee on Publication Ethics (COPE).